Verona Pharma is a clinical‑stage biopharmaceutical company that focuses on developing and commercializing innovative prescription medicines. The company focuses on treating respiratory diseases with important and challenging medical needs, such as COPD, asthma and cystic fibrosis.
Verona Pharma is led by a team with deep industry experience and an indepth background in the discovery, research, development and commercialization of respiratory therapies. The company focuses on developing ensifentrine, which is potentially the first treatment of respiratory disease that combines bronchodilator and anti-inflammatory activity in one compound.
The company aims to enhance health and quality of life for several people that are affected by chronic respiratory diseases. Its development candidate, ensifentrine (RPL554), possesses the potential to offer relief for patients who are suffering from respiratory conditions like chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and asthma.